Reports indicate George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on leave. Multiple outlets report the move follows internal concerns; Tidmarsh had been a central figure overseeing drug reviews at the agency. The personnel shift raises questions about continuity in drug oversight at a time of high-profile regulatory decisions and increased industry scrutiny.